Your session is about to expire
← Back to Search
CAR T-Cell Therapy for Lymphoma
Study Summary
This trial will use T cells and antibodies to create a more effective treatment for cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am 18 years old or older.My lymphoma is between DLBCL and Hodgkin.I have been diagnosed with lymphoma, Waldenstrom's macroglobulinemia, or multiple myeloma.I have been diagnosed with a type of blood cancer that has come back or didn’t respond to treatment.I have another cancer type, but it won't affect this trial's treatment.My lymphoma or CLL/SLL shows kappa-positive expression.I am not pregnant, post-menopausal, or have been surgically sterilized.My organs are functioning well.I am not pregnant or I am post-menopausal.I have had a bone marrow test within the last 28 days for my CLL/SLL.I haven't taken experimental drugs or cancer vaccines in the last 6 weeks.I haven't had chemotherapy or immunotherapy in the last 3 weeks.I am not taking strong inhibitors like fluvoxamine or ciprofloxacin.I am not on any medication that this study does not allow.I do not have any ongoing serious infections.My lymphoma or CLL/SLL is kappa-positive.I can receive standard chemotherapy while waiting for my CAR T-cell therapy.My T-cells have been modified and meet specific quality standards.My doctor thinks I am a good candidate for a specific cell therapy treatment.My last treatment was over 3 weeks ago before starting lymphodepletion.I do not have any ongoing serious infections.My cancer is only in my bone marrow.My cancer returned after a stem cell transplant.My lymphoma is high grade with specific genetic changes.I have a specific type of large B-cell lymphoma.Conditions required for you to participate in the study.My heart is functioning well.I have had at least 2 treatments for my slow-growing lymphoma.My organs are functioning well.I have been tested for hepatitis B and need to check my viral load.I am 18 years old or older.I have had CD19 CAR therapy for my relapsed or hard-to-treat disease.I am using two birth control methods or am not having sex to join this study.I am currently taking 10 mg or more of prednisone daily or its equivalent.My aggressive lymphoma has not responded to at least 2 previous treatments.I have had at least 2 treatments for my chronic leukemia or lymphoma.I have no human anti-mouse antibodies after my last murine antibody treatment.I am mostly able to care for myself but may need occasional help.I have signed the consent form for the CAR-T cell therapy trial before starting lymphodepletion.My organs are functioning well enough for treatment.I have been diagnosed with primary mediastinal large B-cell lymphoma.You have given written permission for your personal health information to be shared with the study team.My brain condition has been stable for at least 3 months.I meet the specific requirements to participate in this study.My diagnosis is diffuse large B-cell lymphoma.
- Group 1: CAR.k.28/CAR.k.4-1BB
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
For what medical condition is CAR.k.28 typically prescribed?
"CAR.k.28 has been used with some success to treat multiple sclerosis, leukemia, myelocytic disorders, acute illnesses and retinoblastoma."
How many participants have signed on to participate in this research project?
"Yes, the evidence available on clinicaltrials.gov reveals that this medical trial is presently recruiting volunteers. The study was first published on November 12th 2020 and was most recently edited on November 28th 2022. 20 individuals need to be recruited at 1 site in order for the research to move forward."
Is the opportunity to participate in this clinical trial still available?
"Affirmative. According to clinicaltrials.gov, this experimental trial which commenced on November 12th 2020 is now looking for participants. 20 individuals need to be enrolled from a single medical facility."
Is there any precedent of utilizing CAR.k.28 in prior investigations?
"At the moment, 946 clinical trials are currently underway to investigate CAR.k.28 with 176 of those in Phase 3. Despite being mainly concentrated around Philadelphia, Pennsylvania, a total of 32476 sites have studies pertaining to this therapeutic intervention."
Are there associated risks when using CAR.k.28?
"The safety of CAR.k.28 is rated at 1 due to the lack of evidence supporting its efficacy and limited data on the drug's potential adverse effects in Phase 1 clinical trials."
Share this study with friends
Copy Link
Messenger